Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Neurosense Therapeutics Ltd NRSN

Alternate Symbol(s):  NRSNW

Healthcare Biotechnology
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3... see more

Current News (NDAQ:NRSN)

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026

PR Newswire December 4, 2025

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

PR Newswire November 24, 2025

NeuroSense to Host Investor Webinar on December 8, 2025

PR Newswire November 3, 2025

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

PR Newswire October 6, 2025

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

PR Newswire September 10, 2025

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

PR Newswire September 4, 2025

NeuroSense Provides Business Update and Progress for the First Half of 2025

PR Newswire August 1, 2025

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

PR Newswire July 22, 2025

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

PR Newswire May 7, 2025
View More News ››

Opinion & Analysis (NDAQ:NRSN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:NRSN)

Excellent YT analysis on NeuroSense!

https://youtu.be/BO-HeQPev4Y?si=O6J1Ybds7-UhiX7v
BryceCanada - February 5, 2024

NRSN .... It held....get ready for possible

Breakout....looking for N.H.O.D  JMHO
Iseneschal - January 19, 2023

NRSN .... In PB mode....has to hold $2.12

and rally or it's toast Cheers !
Iseneschal - January 19, 2023

NRSN .... On watch

$2.50 No position Cheers !
Iseneschal - January 19, 2023

NRSN .... ur on your own Mr. M.....

Not chasing your sh8t
Iseneschal - April 8, 2022

NRSN ....Mr. M ....time to get ur head out of ur a$$

It's Fryday...whack away !!!
Iseneschal - April 8, 2022
View more Bullboard ››

Diagnostear Technologies Inc

Diagnostear Technologies Inc

DiagnosTear Technologies Inc., an ophthalmic company, engages in developing and commercializing disruptive diagnostic ...
View More »

Podcasts